In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will AI Expertise Push Canada Forward As A Biopharma Hub?

Executive Summary

In Canada, an impressive roster of machine learning companies and institutions highlights the research being conducted there. However, a paucity of VC funding and few experienced C-suite leaders has stunted the commercialization of great ideas. 

You may also be interested in...



Sanofi Looks To Atomwise For More AI Help

Deal Snapshot: Following its January AI discovery alliance with Exscientia, Sanofi will employ Atomwise’s platform technology against five undisclosed drug targets.

Bayer’s BD And Licensing Strategy Key To Moving Through Difficult Period

As Bayer moves through a challenging period, business development, licensing and impact investment may help buttress the company’s resilience

What Big Pharmas Are Looking For In Partners

With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel